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Background and purpose: Degenerative change of the corpus callosum might serve
as a clinically useful surrogate marker for net pathological cerebral impact of diabetes
type 1. We compared manual and automatic measurements of the corpus callosum, as
well as differences in callosal cross-sectional area between subjects with type 1 diabetes
and healthy controls.
Materials and methods: This is a cross-sectional study on 188 neurologically
asymptomatic participants with type 1 diabetes and 30 healthy age- and sex-matched
control subjects, recruited as part of the Finnish Diabetic Nephropathy Study. All
participants underwent clinical work-up and brain MRI. Callosal area was manually
measured and callosal volume quantified with FreeSurfer. The measures were normalized
using manually measured mid-sagittal intracranial area and volumetric intracranial
volume, respectively.
Results: Manual and automatic measurements correlated well (callosal area vs. volume:
ρ = 0.83, p < 0.001 and mid-sagittal area vs. intracranial volume: ρ = 0.82, p <
0.001). We found no significant differences in the callosal measures between cases and
controls. In type 1 diabetes, the lowest quartile of normalized callosal area was associated
with higher insulin doses (p = 0.029) and reduced insulin sensitivity (p = 0.033). In
addition, participants with more than two cerebral microbleeds had smaller callosal area
(p = 0.002).
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Conclusion: Manually measured callosal area and automatically segmented are
interchangeable. The association seen between callosal size with cerebral microbleeds
and insulin resistance is indicative of small vessel disease pathology in diabetes type 1.
Keywords: diabetes mellitus, type 1, corpus callosum, volumetry, magnetic resonance imaging,
neurodegeneration
INTRODUCTION
Corpus Callosum (CC) is the largest commissure of the brain,
responsible for much of inter-hemispheric communication (1).
Decrease in cross-sectional sagittal area of the CC (CCA)
has been used as a surrogate for cerebral atrophy, based on
the observation that CCA is proportional to the number of
axons passing through the CC (1, 2), and that callosal axon
density does not decrease with callosal size (1). Furthermore,
as an advantage, CCA does not decrease, or decreases only
slightly (3), with normal aging, up until at least the 7:th-8:th
decade (4, 5).
The number of axons passing through the CC is decreased
by at least two neuro-degenerative processes: cortical atrophy
and neuronal cell death, which cause axonal loss by Wallerian
degeneration, and myelin break-down with central atrophy as
observed in cerebral small vessel disease (6, 7). To get a measure
of callosal shrinkage, and to correct for individual differences in
brain size, CCA can be normalized to mid-sagittal cross-sectional
area (MISS). MISS functions as a surrogate for maximally
attained brain size (4), and this normalized measure does not
differ between the sexes (4).
CCA and MISS can be easily measured in MRI-scans
using the tools available on standard PACS workstations (8).
CCA/MISS could be a useful method to rapidly estimate
pathological CNS effects of disease, possibly as an alternative
to volumetric measurements, that yield the corresponding CC
volume (CCV) and estimated total intracranial volume (eTIV).
The correlation between CCA and CCV or MISS and eTIV
has been studied in a smaller material. The agreement between
measurements made by junior physicians and experienced
neuro-radiologists was found to be excellent, which means that
CCA can be easily measured in routine clinical practice (9).
Not all imaging centers are equipped to routinely perform
volumetry, and simple manual measurements could thus
prove valuable.
We recently observed that neurologically healthy participants
with type 1 diabetes (T1D) had more frequent manifestations
of cerebral small vessel disease on brain MRI compared with
healthy controls (10). Knowing individuals with T1D show clear
signs of early vascular aging (11), our question was whether
premature pathology can be found also in central structures of
the brain.
We hypothesized that individuals with T1D might
have smaller CC size than healthy control subjects and
Abbreviations: CC, Corpus Callosum; CCA, Corpus Callosum Area; MISS, Mid-
sagittal cross-sectional area; CCV, Corpus Callosum Volume; eTIV, Estimated
Total Intracranial Volume; T1D, Type 1 diabetes.
that the signs of small vessel disease might correlate with
CC size.
We first aimed to assess the correlation between CCA/MISS
and CCV/eTIV. Second, we studied, whether CCA/MISS differs
between those with T1D and healthy control subjects, and
whether it is associated with diabetes related traits and/or MRI-
signs of cerebral small vessel disease.
MATERIALS AND METHODS
Study Population
This study is part of the nationwide, prospective Finnish Diabetic
Nephropathy Study. For this cross-sectional sub study, 191
participants with T1D were examined between 2011 and 2017,
and 30 healthy age- and sex-matched control subjects in 2017.
The study design has been described elsewhere in detail (10,
12). T1D was defined as disease onset before 40 years and
insulin treatment initiated within one year of diagnosis. Inclusion
criterion was T1Dwithout history of cerebrovascular disease, and
exclusion criterion the presence of end-stage renal disease. For
this sub study, we excluded one participant with T1D and history
of brain surgery, and two participants with MS, since the disease
influences the CC (13). The controls were non-diabetic age-
and sex-matched volunteers, without first degree relatives having
diabetes. The Ethics committee of Helsinki and Uusimaa Health
District approved our study, and we adhered to the Declaration
of Helsinki.
Clinical Data
All participants underwent a clinical work-up at the Finnish
Diabetic Nephropathy Study center at the Helsinki University
Hospital. This included a thorough review of the patient’s medical
history, anthropometric measurements, as well as questionnaires
about lifestyle factors such as smoking. Blood samples were
drawn and analyzed for HbA1c, lipids and lipoproteins, and
creatinine. Estimated glomerular filtration rate was calculated
with the CKD-EPI formula (14). Urinary albumin excretion rate
was measured from a 24-h urine collection. Insulin sensitivity
was calculated with the formula for the estimated glucose disposal
rate (eGDR) (12, 15).
Diabetic complications were registered, and included
coronary heart disease, retinal photocoagulation, and
albuminuria. None of the study participants had a history
of peripheral arterial disease.
Imaging Protocols and Image Analysis
All participants underwent a brain MRI examination within
1 year from the clinical work-up at the Helsinki Medical
Imaging Center, Helsinki University Hospital, using one 3T
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scanner (Achieva, Philips, Best, The Netherlands), which was not
upgraded, but decommissioned before more control participants
could be recruited. MRI sequences used were part of a standard
protocol and include: T1, T2, FLAIR, T1 MPRAGE, DWI, SWI,
T2∗, and MRA TOF sequences (Supplemental Table 1).
Images were assessed for the following signs of cerebral small-
vessel disease (10): the presence of cerebral micro-bleeds, cortical
superficial siderosis, white-matter hyper-intensities (Fazekas
scale used, with category one considered to be a significant
burden), or lacunes (16, 17). None of the participants had cortical
superficial siderosis.
For manual measurement of CCA andMISS the T1MPRAGE
data set was formatted as straight sagittal slices and inspected in
a mid-sagittal slice, defined by the central axis of the aqueduct.
CCA and MISS were measured by outlining their contours using
the standard area tracing tool of the Agfa Impax workstation, see
Figure 1. Image analysis was done by a senior neuro-radiologist
(J.M.) with >10 years of experience, who was blinded to the
clinical parameters and the results of volumetry. CCA and MISS
were measured three times each at the same occasion, to assess
internal validity of the area measurement.
We normalized CCA to MISS to correct for differences in
maximally attained brain size, and to get a measure of reduction
of CCA.
The FreeSurfer software, version 6.0, was used for volumetry
using the T1MPRAGE sequence, http://surfer.nmr.mgh.harvard.
edu/. FreeSurfer measures CCV by finding the largest white
matter connection between the hemispheres, divides it into a
number of equally long segments, which are then extruded to
yield volumes. The number of segments and extrusion width
is user configurable. Intracranial volume was estimated using
atlas normalization (18). The FreeSurfer rater was masked to
all clinical parameters, radiological findings, and the results of
manual neuroradiological measurements.
Statistical Analysis
All continuous variables were tested for normality of
distribution. Normally distributed variables were tested in
group comparisons with Students t-test or ANOVA (for multiple
groups) and results presented as mean ± standard deviation.
Variables with non-normal distribution were tested for group
differences with Mann–Whitney’s test or Kruskal–Wallis
(for multiple groups) and results presented as medians with
inter-quartile range.
One-way intra-class correlation coefficient test was performed
for the 3 separate measurements of each participant’s CCA and
MISS, for intra-rater reliability. The CCA and MISS reported
are the means of the three separate measurements. Correlation
FIGURE 1 | Schematic illustrations of manually measured 2D areas of CCA (pink), MISS (green) and an example of a FreeSurfer-segmentation of CCV (blue).
FIGURE 2 | Correlation of manually measured callosal area and automated measurements of callosal volume using FreeSurfer. Absolute values (left), ρ = 0.83
(p < 0.001), and normalized to mid-sagittal area or estimated total intracranial volume, respectively (right), ρ = 0.61 (p < 0.001).
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between manual CC measurements and automated volumetric
measurements, as well as correlation between normalized
CCA/MISS, CCV/eTIV, and a compound CCA/eTIV were
examined with Pearson’s or Spearman’s (when not normally
distributed) correlation tests.
Differences in clinical parameters in the T1D group were
assessed between group quartiles based on CCA/MISS. We also
grouped cases based on the number of cerebral microbleeds
(zero, one to two, more than two).
We performed logistic regression on the individuals with
T1D. Outcomes were belonging to the quartile with the smallest
CCAmean/MISSmean vs. any other quartile. Independent variables
were sex, age, insulin dose/kg, eGDR, and number of cerebral
microbleeds. Waist-to-hip ratio was included in a separate model
instead of eGDR due to collinearity. Results are expressed as OR
with 95% CI.
Statistical analysis was done using R (http://www.r-project.
org) version 3.4.3 “Kite-Eating Tree” and p < 0.05 was set as the
threshold for statistical significance.
RESULTS
Callosal Measurements
CCA and MISS measurements had an intra-class correlation
coefficient of 0.989 (95% CI: 0.987–0.992) and 0.996 (95%
CI: 0.995–0.997), respectively. As depicted in Figure 2, the
correlation between CCA and CCV was ρ = 0.83 (p < 0.001).
MISS showed a correlation with eTIV ρ = 0.82 (p < 0.001). The
correlation between normalized CCA/MISS and CCV/eTIV was
ρ= 0.61 (p < 0.001).
When manually inspecting the FreeSurfer-segmented
volumes we found at least part of the fornix to be included in
TABLE 1 | Characteristics of participants according to quartiles of CCA/MISS: Data are percentage, mean ± standard deviation if normally distributed, or median
(inter-quartile range).
Lower quartile, N = 47 Middle quartiles, N = 94 Upper quartile, N = 47 Controls (N = 30) p* p**
CCA/MISS (0.0275, 0.0343) (0.0343, 0.0406) (0.0406, 0.0514) – 0.0389
(0.0361–0.0411)
0.040
Age (years) 39.9 (31.6–44.0) 40.4 (34.4–45.1) 38.9 (32.6–45.6) 38.4 (32.2–42.9) 0.534 0.280
Age at diabetes onset (years) 11.4 (5.6–17.3) 15.2 (9.0–24.5) 14.0 (9.5–24.0) NA (NA–NA) 0.091 –
Diabetes duration (years) 22.8 (18.0–35.3) 21.4 (18.3–29.5) 21.7 (18.4–28.4) NA (NA–NA) 0.589 –
Male gender (%) 49 51 36 43 0.312 –
HbA1c (mmol/mol) 65 (57–73) 66 (59–76) 64 (56–69) 33 (31–34) 0.201 0.000
Insulin dose (IU/kg) 0.59 (0.46–0.77) 0.53 (0.40–0.70) 0.47 (0.37–0.56) NA (NA– NA) 0.029 –
eGDR (mg/kg/min) 7.79 (6.02–9.41) 7.14 (5.39–8.56) 8.46 (6.56–9.17) 10.29 (9.43–10.98) 0.033 0.000
History of smoking (%) 30 39 23 40 0.270 0.951
Established coronary heart
disease (%)
0 1 0 0 0.392 0.572
Retinal photocoagulation (%) 23 23 17 0 0.840 0.004
Urinary albumin excretion
(mg/24h)
13 (11–18) 14 (10–20) 12 (9–16) 13 (11–16) 0.379 0.229
Glomerular filtration rate
[ml/(min*1,73*m2 )]
108 (94–117) 108 (96–113) 108 (100–115) 101 (86–110) 0.210 0.115
Warfarin use (%) 0 1 0 0 0.392 0.572
Aspirin treatment (%) 6 7 11 0 0.851 0.125
Antihypertensive medication (%) 38 40 21 0 0.110 0.000
Body mass index (kg/m2 ) 25.9 (23.9–28.9) 26.5 (24.1–29.8) 25.9 (23.4–28.6) 24.4 (22.2–25.7) 0.643 0.002
Waist to hip ratio 0.87 (0.80–0.95) 0.89 (0.84–0.96) 0.85 (0.80–0.91) 0.85 (0.80–0.92) 0.033 0.014
Systolic blood pressure (mmHg) 130 ± 15 130 ± 14 129 ± 16 121 ± 11 0.646 0.001
Diastolic blood pressure
(mmHg)
76 ± 9 77 ± 8 75 ± 9 78 ± 8 0.388 0.655
Total cholesterol (mmol/l) 4.39 (3.88–5.00) 4.48 (4.06–5.00) 4.40 (4.10–4.79) 4.60 (4.20–5.40) 0.489 0.491
LDL cholesterol (mmol/l) 2.27 (1.73–2.82) 2.44 (2.06–3.01) 2.37 (2.08–2.90) 2.62 (2.33–3.28) 0.346 0.108
HDL cholesterol (mmol/l) 1.59 (1.38–1.80) 1.40 (1.20–1.80) 1.52 (1.27–1.84) 1.46 (1.28–1.66) 0.339 0.854
Triglycerides (mmol/l) 0.92 (0.77–1.27) 1.00 (0.67–1.56) 0.81 (0.64–1.04) 0.84 (0.70–1.24) 0.202 0.244
Lacunar infarctions (%) 4 2 0 0 0.566 0.422
Cerebral microbleeds (%) 28 20 26 3 0.758 0.029
Signs of cerebral small vessel
disease (%)
38 33 36 10 0.927 0.014
p*–between patient quartiles, p**–between controls and middle patient quartiles. Clinical parameters in participants with type 1 diabetes split into quartiles based on normalized
mid-sagittal callosal area. Control subjects are included and compared against the mid quartiles.
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the vast majority of segmentations and that the segmented area
often bleeds outside of the anatomical boarders of the callosum.
We did not correct for this tendency of FreeSurfer to segment
too large CCV.
There were no significant differences between cases and
controls in callosal measurements. CCA/MISS was 0.037 (0.034–
0.041) and 0.039 (0.036–0.041) for the T1D and controls groups
respectively, p= 0.11.
Clinical Parameters
We grouped the participants with T1D based on quartiles of
CCA/MISS, for which clinical and radiological characteristics
appear in Table 1. Those in the lowest quartile of CCA/MISS had
higher daily insulin doses (p = 0.035), Figure 3, and those in the
highest quartile were more insulin sensitive (p= 0.009).
There were no significant differences in the markers of
cerebral small vessel disease between the quartiles of CCA/MISS.
There were, however, a number of participants with several
cerebral microbleeds. When we disregarded participants without
anymicrobleeds, themean number ofmicrobleeds by CCA/MISS
were: lowest quartile 5 (2–18), middle quartiles 1 (1–2), and
highest quartile 1 (1–1), p = 0.003. With the T1D group
subdivided based on the number of cerebral microbleeds (zero
FIGURE 3 | Insulin dose per body weight according to quartile groups based
on callosal area normalized by mid-sagittal intracranial area, p = 0.035.
[N = 144], one to two [N = 32], more than two [N = 12]),
CCA/MISS was 0.037 (0.035–0.040) vs. 0.038 (0.036–0.043) vs.
0.033 (0.031–0.035), p= 0.002, Figure 4.
In logistic regression analysis an independent association was
found between lowest quartile of CCA/MISS and higher insulin
dose: OR per 1 IU/kg 5.38 (95 % CI 1.38–21.04), p = 0.016, as
well as with the presence of more than two cerebral microbleeds
vs. zero: OR 12.00 (2.85–50.65), p= 0.001.
DISCUSSION
Manual and automatic measurements of the CC, MISS and
eTIV, are correlated. We observed significant differences in
clinical characteristics between participants grouped by quartiles
of normalized CCA—those with the smallest CCA had higher
daily insulin doses and those with the largest CCA had the
highest insulin sensitivity. When split by number of cerebral
microbleeds, those with more than two cerebral microbleeds had
smaller normalized CCA. Interestingly, we found no significant
CC differences between cases and controls.
The correlations between CCA to CCV and MISS to eTIV
were ρ = 0.8. Previous studies comparing manually segmented
volumes vs. FreeSurfer have shown similar correlations of r
= 0.74 (19) and r = 0.82 (20) for hippocampal volume.
Segmentation of CCV using FreeSurfer has been evaluated
by comparison to manually corrected CCV-segmentation, and
found to perform very well (21). This was however using a
previous version of FreeSurfer. With version 6.0, we find that
FreeSurfer-segmented CCV tends to be too large compared
to CCA outlined by an experienced neuro-radiologist. This is
because of frequent inclusion of a variably large part of the fornix
as well as bleeds of the segmented area outside the callosum.
The variable error thus introduced causes the correlation of CCA
vs. CCV to suffer. FreeSurfer version 6.0 was however found to
correlate well with manual measurement using the longitudinal
stream by Platten et al. (9). The correlation was worse using the
cross-sectional stream as is the case in the present study.
One potential advantage of CCV over CCA is the ability of
FreeSurfer to deal with amisaligned or skewedmid-line. It should
however be possible to overcome any problems with misaligned
FIGURE 4 | Callosal size by number of cerebral microbleeds in participants with type 1 diabetes. Manually measured callosal area normalized by mid-sagittal
intracranial area (left), p = 0.002, and callosal volume normalized by estimated total intracranial volume as measured by FreeSurfer (right), p = 0.018.
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mid-lines even in clinical practice given the almost universal
availability of 3D-imaging and multi planar reconstruction. The
biggest contributor to the discrepancy in the present study
between manual and FreeSurfer based callosal measurements is
the above mentioned tendency to over-segmentation.
The correlation for CCA/MISS and CCV/eTIV was weaker,
ρ = 0.6, which may be because the planar measurements did
not encompass skull width. Because it does take skull width
into account, the volumetric eTIV (18), is a conceptually better
estimate of total intracranial volume than MISS. CCA/eTIV
could be an attractive normalized measure, although it did not
provide any stronger correlation with the clinical parameters
than CCA/MISS or CCV/eTIV, or differ between cases and
controls in our cohort (data not shown).
In our study, the intraclass correlations of the CCA and
MISS measurements were excellent. Repeated measurements in
the same slice using standard PACS area-tracing tools gave
highly uniform results suggesting there is no advantage to
multiple averaged measurements over single measurements.
CCA measurements have been found to be highly repeatable
regardless of operator experience (9).
The mean CCA for our control participants was 6.16 cm2,
which is close to those reported byMitchell et al. (22) and Sullivan
et al. (4).
We found an association between CC atrophy and cerebral
microbleeds. This finding may indicate that the underlying small
vessel disease in individuals with T1D, to the extent it is causing
the microbleeds, is associated with further brain degeneration.
More than 5 micro-bleeds indicate higher risk of future cerebral
hemorrhage and might influence treatment choices (23).
Callosal atrophy has been observed in diseases with white
matter lesions secondary to cerebral small vessel disease, such
as vascular dementia and CADASIL (24). Future studies will tell
whether the changes observed in our study will translate into
cognitive impairment.
We found higher insulin dose, suggesting insulin resistance,
to be associated with decreased CCA. This is supported
by higher eGDR, indicating higher insulin sensitivity, being
associated with larger CCA. Interestingly, insulin resistance
and/or hyperinsulinemia has been implicated in the pathogenesis
of Alzheimer’s disease (25). In T1D, on the other hand, CNS
involvement such as cognitive impairment has been associated
with white matter atrophy (26) and retinopathy (27, 28).
In type 2 diabetes, a non-significant trend toward atrophy of
the CC has been noted compared to healthy controls (29). CC
atrophy has also been observed in MS, where it associates with
decreasing cognitive ability, disease duration, and other measures
of disease severity (13). Similarly, in people with Alzheimer’s and
Parkinson’s disease CC atrophy is associated with more severe
disease stages (30–32). This is in line with our results, as no
significant difference was shown in CC size between healthy
controls and neurologically asymptomatic individuals with T1D.
The lack of difference in our cohort may, thus, indicate that the
CC is less affected at the early disease stages in young individuals.
The strengths of our study include a well-defined and
thoroughly clinically characterized cohort. Our measurements
were done on the same sequences with imaging performed on the
same scanner. The mid-sagittal area for each scan was defined
by a technician, masked to the study, which further limits bias
of measurements. Limitations include the rather low number of
control participants, which limits the ability of the study to detect
small group differences and increases the risk of type 2 errors, as
well as the cross-sectional design of the study.
CONCLUSION
Manual cross-sectional and automatic volume measurements of
the CC correlate well. CC size does not differ between T1D and
control groups. However, multiple cerebral micro-bleeds, eGDR
(as amarker of lower insulin sensitivity), and higher insulin doses
were associated with CC size in T1D. This indicates a silent role
of small vessel disease in early T1D that does impact brain health.
Future studies will focus on T1D and brain health longitudinally.
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